A drug called Lu177-PSMA-617 may be a new option for treating advanced prostate cancer. In a large clinical trial called VISION, participants who received 177Lu-PSMA-617—a type of drug called a radiopharmaceutical—along with standard treatments lived longer than those who received only standard therapies.
